HDAC2 and acute myeloid leukemia: This HDAC2‐dependent miRNA signature in AML highlights the potentially beneficial effects of treatment with epigenetic drugs alone or in combination with other therapies (including immunotherapy) acting via a targeted mechanism involving the perturbation of genes affecting cell cycle, proliferation, apoptosis, and immune system.